Allison Bratzel
Stock Analyst at Piper Sandler
(4.70)
# 168
Out of 4,711 analysts
32
Total ratings
69.57%
Success rate
23.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Neutral | $12 → $22 | $17.18 | +28.06% | 2 | Nov 14, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $15 → $23 | $17.09 | +34.58% | 2 | Nov 14, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $65 → $62 | $35.63 | +74.01% | 1 | Nov 14, 2024 | |
| ARGX argenx SE | Maintains: Overweight | $553 → $620 | $623.82 | -0.61% | 12 | Nov 1, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Overweight | $28 → $42 | $44.78 | -6.21% | 3 | Oct 15, 2024 | |
| ROIV Roivant Sciences | Maintains: Overweight | $20 → $22 | $11.57 | +90.15% | 2 | Jul 10, 2024 | |
| HUMA Humacyte | Maintains: Neutral | $4 | $4.64 | -13.79% | 2 | Mar 26, 2024 | |
| SLDB Solid Biosciences | Upgrades: Overweight | $8 → $20 | $4.16 | +380.77% | 4 | Mar 14, 2024 | |
| ABCL AbCellera Biologics | Assumes: Overweight | $20 | $2.85 | +601.75% | 1 | Oct 13, 2023 | |
| REPL Replimune Group | Assumes: Overweight | $44 | $12.49 | +252.28% | 1 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 | $68.84 | +45.26% | 2 | Feb 8, 2023 |
Travere Therapeutics
Nov 14, 2024
Maintains: Neutral
Price Target: $12 → $22
Current: $17.18
Upside: +28.06%
Rigel Pharmaceuticals
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $17.09
Upside: +34.58%
Ionis Pharmaceuticals
Nov 14, 2024
Maintains: Overweight
Price Target: $65 → $62
Current: $35.63
Upside: +74.01%
argenx SE
Nov 1, 2024
Maintains: Overweight
Price Target: $553 → $620
Current: $623.82
Upside: -0.61%
Scholar Rock Holding
Oct 15, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $44.78
Upside: -6.21%
Roivant Sciences
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $11.57
Upside: +90.15%
Humacyte
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $4.64
Upside: -13.79%
Solid Biosciences
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $4.16
Upside: +380.77%
AbCellera Biologics
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $2.85
Upside: +601.75%
Replimune Group
Apr 17, 2023
Assumes: Overweight
Price Target: $44
Current: $12.49
Upside: +252.28%
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $68.84
Upside: +45.26%